Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × NP-G2-044 × Clear all
NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡